Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acro Biomedical CoACBM Equity-to-Asset is -111.25 as of Jun. 2026. The stock has 2 warning signs investors should review. Among 543 Diversified Financial Services companies, Acro Biomedical Co ranks worse than 98.16% on this metric.
The historical rank and industry rank for Acro Biomedical Co's Equity-to-Asset or its related term are showing as below:
ACBM'
s Equity-to-Asset Range Over the Past 10 Years
Min: -111.25 Med: 0.7 Max: 0.93
Current: -111.25
During the past 11 years, the highest Equity to Asset Ratio of Acro Biomedical Co was 0.93. The lowest was -111.25. And the median was 0.70.
ACBM's Equity-to-Asset is ranked worse than 98.16% of 543
companies
in the Diversified Financial Services industry
Industry Median: 0.9
vs ACBM: -111.25
Acro Biomedical Co (OTCPK:ACBM) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Acro Biomedical Co Equity-to-Asset Related Terms
Acro Biomedical Co Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Acro Biomedical Co's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACBM vs RNGC, EEGI, AGIN: Equity-to-Asset Comparison
For the Shell Companies subindustry, Acro Biomedical Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acro Biomedical Co Equity-to-Asset vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, Acro Biomedical Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Acro Biomedical Co's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Acro Biomedical Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acro Biomedical Co (ACBM) has a Equity-to-Asset of -111.25 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Acro Biomedical Co and its competitors. According to the industry distribution chart, Acro Biomedical Co ranks #533 out of 543 companies in the Diversified Financial Services industry, placing it in the top 98.2%.
Is Acro Biomedical Co's Equity-to-Asset too high?
Acro Biomedical Co's current Equity-to-Asset is -111.25. Based on the distribution chart, Acro Biomedical Co ranks #533 out of 543 companies in the Diversified Financial Services industry, which is in the bottom quartile relative to peers.
How does Acro Biomedical Co's Equity-to-Asset compare to RNGC and EEGI?
According to the Diversified Financial Services industry distribution chart, Acro Biomedical Co ranks #533 out of 543 companies for Equity-to-Asset. This places Acro Biomedical Co in the lower half of its industry. The industry median Equity-to-Asset is 0.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Diversified Financial Services company?
The median Equity-to-Asset among Diversified Financial Services companies is 0.90, based on 543 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Acro Biomedical Co and its competitors. For the Diversified Financial Services industry, the median Equity-to-Asset is 0.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acro Biomedical Co's current Equity-to-Asset is -111.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acro Biomedical Co stock overvalued right now?
Acro Biomedical Co (ACBM) has a current Equity-to-Asset of -111.25. The current Equity-to-Asset is -111.25. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Acro Biomedical Co (ACBM), the current Equity-to-Asset is -111.25 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACBM has been successfully added to your 
